Svs3b Inhibitors
Svs3b inhibitors are a class of chemical compounds that target the Svs3b enzyme. This enzyme, like others in its family, plays a critical role in various biological pathways, where it is involved in catalyzing specific biochemical reactions. The precise function of Svs3b is typically characterized by its involvement in the metabolism of certain substrates, which can have wide-ranging effects on cellular processes. Inhibitors of this enzyme are designed to interact with the active site or other critical regions of the enzyme, effectively blocking its function. This inhibition can be competitive, where the inhibitor mimics the substrate and competes for the active site, or non-competitive, where the inhibitor binds to a different part of the enzyme, inducing a conformational change that reduces its activity.
The design and development of Svs3b inhibitors involve a deep understanding of the enzyme's structure and the mechanisms by which it interacts with its substrates. Researchers utilize various techniques such as X-ray crystallography, molecular docking, and structure-activity relationship studies to identify potential inhibitory compounds that have high specificity and potency against Svs3b. These studies often involve the synthesis of numerous derivatives of promising compounds, followed by rigorous testing to ascertain their ability to inhibit the enzyme in vitro and in cellular models. The physicochemical properties of these inhibitors, such as their solubility, stability, and reactivity, are crucial factors that are meticulously optimized to enhance their interaction with Svs3b. Also, the selectivity of these inhibitors is of paramount importance to prevent off-target effects that could disrupt other enzymatic pathways. The development of Svs3b inhibitors is a complex process that draws from various fields of chemistry, including medicinal chemistry, organic chemistry, and biochemistry, to achieve compounds that can precisely modulate the activity of the Svs3b enzyme.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a specific inhibitor of phosphoinositide 3-kinases (PI3K). By inhibiting PI3K, it prevents the phosphorylation and activation of AKT, a downstream effector in the PI3K pathway. Since Svs3b is regulated by the AKT signaling pathway, the inhibition of PI3K leads to a decrease in Svs3b activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is another PI3K inhibitor, similar in function to Wortmannin. It blocks the PI3K-dependent activation of AKT, thereby indirectly inhibiting Svs3b activity by preventing its phosphorylation and subsequent activation. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an mTOR inhibitor that obstructs the mTORC1 complex, which is involved in protein synthesis and cell growth. Since Svs3b activity can be upregulated by mTORC1-mediated pathways, rapamycin leads to reduced Svs3b functionality. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $102.00 $138.00 | 14 | |
Triciribine is an AKT inhibitor that prevents the activation of AKT by blocking its phosphorylation. Without active AKT, Svs3b, which is activated downstream of AKT, has reduced activity. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is a MEK inhibitor that disrupts the MAPK/ERK pathway, which can interact with the PI3K/AKT pathway. By inhibiting MEK, U0126 can indirectly decrease Svs3b activity by modulating the pathways that converge on AKT, the upstream regulator of Svs3b. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is another MEK inhibitor that functions similarly to U0126, leading to a decrease in ERK activation. Inhibited ERK activity can result in lower Svs3b activity due to reduced cross-talk stimulation from the MAPK/ERK pathway to the PI3K/AKT pathway. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a p38 MAPK inhibitor that can indirectly affect Svs3b activity by modulating stress response pathways that may influence PI3K/AKT signaling. By inhibiting p38, the stress-induced activation of Svs3b can be diminished. | ||||||
PP242 | 1092351-67-1 | sc-301606A sc-301606 | 1 mg 5 mg | $56.00 $169.00 | 8 | |
PP242 is a selective inhibitor of mTOR kinase that targets both mTORC1 and mTORC2 complexes. Inhibition of these complexes can lead to reduced Svs3b activity due to the role of mTOR signaling in Svs3b regulation. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK). JNK is part of the MAPK pathway and can regulate various proteins, including those in the PI3K/AKT pathway. By inhibiting JNK, SP600125 may lead to a reduction in Svs3b activity. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib is a tyrosine kinase inhibitor that primarily targets BCR-ABL and Src family kinases. By inhibiting these kinases, Dasatinib can indirectly affect Svs3b activity through the interruption of signaling pathways that interact with the PI3K/AKT pathway. | ||||||